Trazodone

CHEMBL621 Phase 4 معتمد Small molecule

Half-Life

5-9 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

371.9 g/mol

LogP

2.8

Phase

4

Serotonin antagonism combined with reuptake inhibition places trazodone in the SARI category, distinct from the SSRIs in its receptor profile. It blocks serotonin receptors while inhibiting the serotonin transporter, with comparatively little action on other neurotransmitter systems, and it also engages the histamine H1 receptor. That antihistaminic component produces the sedation for which the drug is extensively used off-label in insomnia, alongside its approved role in depression. Unlike many hypnotics it is generally not habit-forming, a property that shapes prescribing preferences. A short elimination half-life of about five to nine hours accompanies its nervous-system classification. The molecule is C19H22ClN5O with a mass near 371.9 g/mol.

This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

الوزن الجزيئي

371,8640 g/mol

LogP

2,80

TPSA

42,40 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Psychiatry Insomnia HIV/AIDS Major Depressive Disorder

تصنيفات الأدوية

N — N - Nervous System

Pharmacokinetics (PK)

Half-Life 5-9 hours

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12

InChI

InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2

Molecular Formula

C19H22ClN5O

HBD / HBA

- / 4

الروابط القابلة للدوران

5

الذرات الثقيلة

26

HRH1 (Histamine H1 Receptor) Antagonist

SLC6A4 (Serotonin Transporter) Inhibitor

Moderate Trazodone + Sertraline

Sertraline combined with trazodone may increase the risk of serotonin syndrome due to additive serotonergic effects.

Moderate Trazodone + Fluoxetine

Fluoxetine inhibits CYP2D6-mediated metabolism of trazodone, significantly increasing trazodone plasma levels and serotonin syndrome risk.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

Key pharmacokinetic parameters for Trazodone: Half-life: 5-9 hours.

Yes, Trazodone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL621. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5533. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Trazodone على PillFYI

البنية

بيانات سريعة

Class: N - Nervous System
الصيغة الجزيئية: C19H22ClN5O
المرادفات: 2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.